PFE

The updated vaccine specifically addresses the XBB.1.5 subvariant of the Omicron variant, which has raised concerns due to its potential to evade immunity conferred by earlier versions of the vaccine. 

Both COVID-19 sales and Paxlovid contributed immensely to the impressive financial report Pfizer announced for Q2 2022.